Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...
Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating advanced cervical cancer by ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
A cervical cancer drug may elevate the risk of developing ocular surface disease, such as conjunctival scarring and infectious keratitis.
Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
The Scottish Medicines Consortium (SMC) gave the green light to three new cancer treatments, as well as a drug to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback